Bisphosphonate anticancer activity

Bibliography

• Litpon A. Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates. Expert Opin Pharmacother 2011;12(5):749-62
   Google Scholar
• Widler R, Jaeggi KA, Glatt M, Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 2002;45:3721-38
   PubMed Web of Science ®Google Scholar
• Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA. Antiresorptive dose–response relationship across three generations of bisphosphonates. Drugs Exp Clin Res 1989;15:389-96
   PubMedGoogle Scholar
• Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-51
   PubMed Web of Science ®Google Scholar
• Van Beek E, Pieterman E, Cohen L, Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999;264:108-11
   PubMed Web of Science ®Google Scholar
• Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241-69
   PubMed Web of Science ®Google Scholar
• Van Beek E, Lowik C, Van Der Pluijm G, Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999;14:722-9
   PubMed Web of Science ®Google Scholar
• Hasmin M, Bieler G, Ruegg G. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylationdependent signalling pathways. J Thromb Haemost 2007;5:166-73
   PubMed Web of Science ®Google Scholar
• Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001;61:4418-24
   PubMed Web of Science ®Google Scholar
• Senaratne SG, Pirianov G, Mansi JL, Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-68
   PubMed Web of Science ®Google Scholar
• Santini D, Fratto ME, Vincenzi B, Zoledronic acid in the management of metastatic bone disease. Expert Opin Biol Ther 2006;6:1333-48
   PubMed Web of Science ®Google Scholar
• Boissier S, Ferreras M, Peyruchaud O, Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-54
   PubMed Web of Science ®Google Scholar
• Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999;83:263-9
   PubMed Web of Science ®Google Scholar
• Major PP, Cook RJ, Chen BL, Survival-adjusted cumulative event analysis of skeletal-related events in patients with cancer metastatic to bone in trials of zoledronic acid. Presented at ‘What is new in bisphosphonates?’, 7th workshop on bisphosphonates: ‘from the laboratory to the patient’, 24 – 26 March 2004, Davos, Switzerland
   Google Scholar
• Santini D, Vincenzi B, Avvisati G, Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8:1080-4
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Dicuonzo G, Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003;9:2893-7
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Santini D, Dicuonzo G, Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005;25:144-51
   PubMed Web of Science ®Google Scholar
• Croucher PI, De Hendrik R, Perry MJ, Zoledronic acid treatment of 5T2MMbearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003;18:482-92
   PubMed Web of Science ®Google Scholar
• Gouin F, Gory B, Redini F, Heymann D. Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer 2006;119:980-4
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Pearse RN, Johnson CL, Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002;116:278-90
   PubMed Web of Science ®Google Scholar
• Hiraga T, Williams PJ, Ueda A, Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004;10:4559-67
   PubMed Web of Science ®Google Scholar
• De Libero G. Sentinel function of broadly reactive human gammadelta T cells. Immunol Today 1997;18:22-6
   PubMedGoogle Scholar
• Caccamo N, Meraviglia S, Scarpa F, Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more. Expert Opin Biol Ther 2008;8:875-83
   PubMed Web of Science ®Google Scholar